5FU and oxaliplatin-containing chemotherapy in two dihydropyrimidine dehydrogenase-deficient patients
Reerink, O.; Mulder, N.H.; Szabo, B.G.; Hospers, G.A.P.
Anticancer Research 24(3b): 1969-1971
2004
ISSN/ISBN: 0250-7005 PMID: 15274386 Document Number: 579831
Patients with a germline mutation leading to a deficiency of the dihydropyrimidine dehydrogenase (DPD) enzyme are at risk from developing severe toxicity on the administration of 5FU-containing chemotherapy. We report on the implications of this inborn genetic error in two patients who received 5FU and oxaliplatin. A possible co-medication effect of oxaliplatin is considered, as are the consequences of screening for DPD deficiency.
Document emailed within 1 workday
Related Documents
Toshima, T.; Kodera, M.; Yamashita, Y.; Oishi, M.; Seshimo, K.; Yamamura, M.; Kato, H.; Ikeda, H.; Mizuno, K. 2013: A case in which dihydropyrimidine dehydrogenase deficiency was strongly suspected during adjuvant chemotherapy with capecitabine for colon cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 40(11): 1549-1552Katayose, Y.; Nakagawa, K.; Onogawa, T.; Yoshida, H.; Motoi, F.; Naitoh, T.; Rikiyama, T.; Egawa, S.; Unno, M. 2011: A case of hypersensitivity reaction to reintroduced-oxaliplatin at the second course of oxaliplatin-based chemotherapy after neoadjuvant chemotherapy for liver metastases from colon cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 38(13): 2651-2653
Ishida, H.; Yamada, H.; Shirakawa, K.; Nakada, H.; Ohsawa, T.; Takeuchi, I.; Okada, N.; Yokoyama, M.; Inokuma, S.; Suzuki, T.; Odaka, A.; Hoshino, T.; Murata, N.; Hashimoto, D.; Itoyama, S.; Mori, T.; Matsumoto, Y.; Miura, T. 2003: Results of prophylactic hepatic arterial chemotherapy for liver metastases of Dukes C colorectal cancer--correlation with tumoral expression of dihydropyrimidine dehydrogenase, thymidylate synthase, p53, or orotate phosphoribosyl transferase Gan to Kagaku Ryoho. Cancer and ChemoTherapy 30(11): 1621-1626
Sakurai, Y.; Furuta, S.; Sunagawa, R.; Tonomura, S.; Inaba, K.; Shoji, M.; Nakamura, Y.; Isogaki, J.; Komori, Y.; Uyama, I.; Kamoshida, S.; Tsutsumi, Y. 2007: Orotate phosphoribosyltransferase levels in gastric carcinoma and normal gastric mucosa - correlation with thymidylate synthase and dihydropyrimidine dehydrogenase levels and the changes after neoadjuvant chemotherapy Gan to Kagaku Ryoho. Cancer and ChemoTherapy 34(10): 1581-1587
Kawasaki, G.; Yoshitomi, I.; Yanamoto, S.; Yamada, S.-I.; Kawano, T.; Mizuno, A. 2010: Immunohistochemical and clinicopathological study of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyl transferase expression in oral cancer patients responding to UFT Gan to Kagaku Ryoho. Cancer and ChemoTherapy 37(6): 1035-1039
Qian, J.; Qin, S.-k.; Mei, J.-f.; Chen, Y.-x.; Shao, Z.-j.; He, Z.-m. 2004: Oxaliplatin plus capecitabine as a second line chemotherapy for patients with advanced gastric cancer Zhonghua Zhong Liu Za Zhi 26(12): 746-748
Furuhata, T.; Kawakami, M.; Okita, K.; Kimura, Y.; Kihara, C.; Tsuruma, T.; Ohmura, T.; Yamaguchi, K.; Hata, F.; Katsuramaki, T.; Sasaki, K.; Hirata, K. 2006: Plasma level of a 5-fluorouracil metabolite, fluoro-beta-alanine correlates with dihydropyrimidine dehydrogenase activity of peripheral blood mononuclear cells in 5-fluorouracil treated patients Journal of Experimental and Clinical Cancer Research: Cr 25(1): 79-82
Milano, G.; Etienne, M.C. 1994: Dihydropyrimidine dehydrogenase (DPD) and clinical pharmacology of 5-fluorouracil (review) Anticancer Research 14(6a): 2295-2297
Ishikawa, Y.; Kubota, T.; Otani, Y.; Watanabe, M.; Teramoto, T.; Kumai, K.; Takechi, T.; Okabe, H.; Fukushima, M.; Kitajima, M. 1999: Thymidylate synthetase and dihydropyrimidine dehydrogenase levels in gastric cancer Anticancer Research 19(6c): 5635-5640
Shitara, K.; Munakata, M.; Muto, O.; Kasai, M.; Okada, R.; Mitobe, S.; Sakata, Y. 2007: Oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4) as salvage chemotherapy in patients with pretreated colorectal cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 34(7): 1079-1084
Mazur, A.; Figurski, S.; Płoskoń, A.; Meijer, J.; Zoetekouw, L.; Watróbska, S.ła.; Sykut-Cegielska, J.; Gradowska, W.; van Kuilenburg, A.é B.P. 2008: Dihydropyrimidine dehydrogenase deficiency presenting with psychomotor retardation in the first Polish patient Acta Biochimica Polonica 55(4): 787-790
Hoff, P.M.; Pazdur, R. 1999: Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines: a novel class of oral antineoplastic agents Seminars in Oncology 26(6 Suppl 18: 52-56
Shahrokni, A.; Rajebi, M.R.; Harold, L.; Saif, M.W. 2009: Cardiotoxicity of 5-fluorouracil and capecitabine in a pancreatic cancer patient with a novel mutation in the dihydropyrimidine dehydrogenase gene Jop: Journal of the Pancreas 10(2): 215-220
Komuro, Y.; Watanabe, T.; Tsuno, N.; Kitayama, J.; Inagaki, N.; Nishida, M.; Nagawa, H. 2003: The usefulness of immunohistochemical evaluation of dihydropyrimidine dehydrogenase for rectal cancer treated with preoperative radiotherapy Hepato-Gastroenterology 50(52): 906-911
Shimizu, T.; Yamada, Y.; Yasui, H.; Shirao, K.; Fukuoka, M. 2005: Clinical application of immunoreactivity of dihydropyrimidine dehydrogenase (DPD) in gastric scirrhous carcinoma treated with S-1, a new DPD inhibitory fluoropyrimidine Anticancer Research 25(4): 2997-3001
Tokunaga, Y.; Nakagami, M.; Tokuka, A.; Ohsumi, K. 2003: Prognostic effects of dihydropyrimidine dehydrogenase in advanced colorectal cancer after surgery: immunohistochemistry using a new monoclonal antibody Anticancer Research 23(2C): 1763-1768
Taniguchi, M.; Yano, M.; Tsujinaka, T.; Ogawa, A.; Morita, S.; Kaneko, K.; Akiyama, Y.; Miki, H.; Monden, M. 2003: Parenteral nutrition decreases hepatic dihydropyrimidine dehydrogenase activity and modulates catabolism of 5-fluorouracil in rats In Vivo 17(3): 219-223
Imaizumi, H.; Ishibashi, K.; Okada, N.; Tajima, Y.; Amano, K.; Hatano, S.; Kuwabara, K.; Sobajima, J.; Ishiguro, T.; Ohsawa, T.; Kumamoto, K.; Kumagai, Y.; Haga, N.; Ishida, H. 2012: Clinical outcomes in refractory colorectal cancer patients with wild-type K-ras treated with bevacizumab and oxaliplatin-based chemotherapy as a first-line treatment Gan to Kagaku Ryoho. Cancer and ChemoTherapy 39(12): 2185-2188
Nagano, H.; Ichikawa, W.; Simizu, M.; Shirota, Y.; Nihei, Z. 2004: Thymidylate synthase and dihydropyrimidine dehydrogenase gene expressions in colorectal cancer using the Danenberg tumor profile method Gan to Kagaku Ryoho. Cancer and ChemoTherapy 31(6): 889-892
Hsiao, S-Chuan.; Lin, J-Fen.; Chuang, M-Te.; Lee, Y-An.; Wu, D-Long. 2009: Retrospectively comparative evaluation of the first- and second-line chemotherapy with campto and oxaliplatin combined with oral tegafur/uracil (UFT)/leucovorin (LV) in patients with metastatic colorectal cancer International Surgery 94(4): 298-303